Prognostic value of cell cycle regulatory proteins in muscle-infiltrating bladder cancer

Abstract

Purpose: The aims of this study were to investigate the expression levels of proteins involved in cell cycle regulation in specimens of bladder cancer and to correlate them with the clinicopathological characteristics, proliferative activity and survival.

Methods: Eighty-two specimens obtained from patients affected by muscle-invasive bladder cancer were evaluated immunohistochemically for p53, p21 and cyclin D1 expression, as well as for the tumour proliferation index, Ki-67. The statistical analysis included Kaplan-Meier curves with log-rank test and Cox proportional hazards models.

Results: In univariate analyses, low Ki-67 proliferation index (P = 0.045) and negative p21 immunoreactivity (P = 0.04) were associated to patient's overall survival (OS), but in multivariate models p21 did not reach statistical significance. When the combinations of the variables were assessed in two separate multivariate models that included tumour stage, grading, lymph node status, vascular invasion and perineural invasion, the combined variables p21/Ki-67 or p21/cyclin D1 expression were independent predictors for OS; in particular, patients with positive p21/high Ki-67 (P = 0.015) or positive p21/negative cyclin D1 (P = 0.04) showed the worst survival outcome.

Conclusions: Important alterations in the cell cycle regulatory pathways occur in muscle-invasive bladder cancer and the combined use of cell cycle regulators appears to provide significant prognostic information that could be used to select the patients most suitable for multimodal therapeutic approaches.

Fig. 1

Kaplan–Meier curves for overall survival according to Ki-67 (a); p21 (b); cyclin D1 (c) and p53 (d) expression. Numbers of patients at risk are provided at 1 and 2 years

Fig. 2

Kaplan–Meier curves for overall survival according to p21 expression combined with either Ki-67 (a) or cyclin D1 (b). a A group A, negative p21/low Ki-67; B group B, negative p21/high Ki-67 or positive p21/low Ki-67, C group C, positive p21/high Ki-67. b A group A, negative p21/positive cyclin D1; B group B, negative p21/negative cyclin D1 and positive p21/positive cyclin D1; C group C, positive p21/negative cyclin D1. Numbers of patients at risk are provided at 1 and 2 years